Aktie 300683 WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Wuhan Hiteck Biological Pharma Co.,Ltd

Aktien

300683

CNE1000034C5

300683

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 26.04.2024 		% 5 Tage % 1. Jan.
23,82 CNY +1,49 % Intraday Chart für Wuhan Hiteck Biological Pharma Co.,Ltd +9,42 % -34,03 %
21.04. Wuhan Hiteck Biological Pharma Co.,Ltd meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
2023 Wuhan Hiteck Biological Pharma Co.,Ltd meldet Ergebnis für die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
Hiteck Biological Pharma Gets Nod to Trial Eye Drops
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it has received CNY 294.999985 million in funding from Nuode Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Shanghai Boshen Investment Center (Limited Partnership), Shenzhen Qianhai Eagle Fund Management Co., Ltd., UBS Group AG, Guodu Venture Capital Co., Ltd., and other investors
Hiteck Biological Pharma Gets Regulatory Consent for Share Sale
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it expects to receive CNY 300 million in funding
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
Wuhan Hiteck Biological Pharma Co.,Ltd Approves Board Appointments
Wuhan Hiteck Biological Pharma Co.,Ltd agreed to acquire additional 6.9416% stake in Beijing Shadong Biotechnology Co., Ltd. from Beijing Zhongguancun VC Development Co., Ltd.
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
Wuhan Hiteck Biological Pharma : Bio-Pharma Nets $91 Million From Private Placement
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
Wuhan Hiteck Biological Pharma Co., Ltd. announced that it has received CNY 599.972 million in funding from a group of investors
Xiweiai Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Wuhan Hiteck Biological Pharma Co.,Ltd
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 300683 Aktie
  4. Nachrichten Wuhan Hiteck Biological Pharma Co.,Ltd
  5. Andere Sprachen